Use of single-agent pembrolizumab as first-line treatment for non-small cell lung cancer with PDL1 status 50% as per NHS England interim guidance during the COVID-19 pandemic at Southend University Hospital

Detalles Bibliográficos
Autores principales: Sen, Rebecca, Islam, Rafiqul Islam, Baker, Harriet, Kim, Samuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. Published by Elsevier B.V. 2021
Materias:
COVID and Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8159539/
http://dx.doi.org/10.1016/S0169-5002(21)00241-5
_version_ 1783700111652552704
author Sen, Rebecca
Islam, Rafiqul Islam
Baker, Harriet
Kim, Samuel
author_facet Sen, Rebecca
Islam, Rafiqul Islam
Baker, Harriet
Kim, Samuel
author_sort Sen, Rebecca
collection PubMed
description
format Online
Article
Text
id pubmed-8159539
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-81595392021-05-28 Use of single-agent pembrolizumab as first-line treatment for non-small cell lung cancer with PDL1 status 50% as per NHS England interim guidance during the COVID-19 pandemic at Southend University Hospital Sen, Rebecca Islam, Rafiqul Islam Baker, Harriet Kim, Samuel Lung Cancer COVID and Cancer Elsevier B.V. Published by Elsevier B.V. 2021-06 2021-05-28 /pmc/articles/PMC8159539/ http://dx.doi.org/10.1016/S0169-5002(21)00241-5 Text en Copyright © 2021 Elsevier B.V. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle COVID and Cancer
Sen, Rebecca
Islam, Rafiqul Islam
Baker, Harriet
Kim, Samuel
Use of single-agent pembrolizumab as first-line treatment for non-small cell lung cancer with PDL1 status 50% as per NHS England interim guidance during the COVID-19 pandemic at Southend University Hospital
title Use of single-agent pembrolizumab as first-line treatment for non-small cell lung cancer with PDL1 status 50% as per NHS England interim guidance during the COVID-19 pandemic at Southend University Hospital
title_full Use of single-agent pembrolizumab as first-line treatment for non-small cell lung cancer with PDL1 status 50% as per NHS England interim guidance during the COVID-19 pandemic at Southend University Hospital
title_fullStr Use of single-agent pembrolizumab as first-line treatment for non-small cell lung cancer with PDL1 status 50% as per NHS England interim guidance during the COVID-19 pandemic at Southend University Hospital
title_full_unstemmed Use of single-agent pembrolizumab as first-line treatment for non-small cell lung cancer with PDL1 status 50% as per NHS England interim guidance during the COVID-19 pandemic at Southend University Hospital
title_short Use of single-agent pembrolizumab as first-line treatment for non-small cell lung cancer with PDL1 status 50% as per NHS England interim guidance during the COVID-19 pandemic at Southend University Hospital
title_sort use of single-agent pembrolizumab as first-line treatment for non-small cell lung cancer with pdl1 status 50% as per nhs england interim guidance during the covid-19 pandemic at southend university hospital
topic COVID and Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8159539/
http://dx.doi.org/10.1016/S0169-5002(21)00241-5
work_keys_str_mv AT senrebecca useofsingleagentpembrolizumabasfirstlinetreatmentfornonsmallcelllungcancerwithpdl1status50aspernhsenglandinterimguidanceduringthecovid19pandemicatsouthenduniversityhospital
AT islamrafiqulislam useofsingleagentpembrolizumabasfirstlinetreatmentfornonsmallcelllungcancerwithpdl1status50aspernhsenglandinterimguidanceduringthecovid19pandemicatsouthenduniversityhospital
AT bakerharriet useofsingleagentpembrolizumabasfirstlinetreatmentfornonsmallcelllungcancerwithpdl1status50aspernhsenglandinterimguidanceduringthecovid19pandemicatsouthenduniversityhospital
AT kimsamuel useofsingleagentpembrolizumabasfirstlinetreatmentfornonsmallcelllungcancerwithpdl1status50aspernhsenglandinterimguidanceduringthecovid19pandemicatsouthenduniversityhospital

Ejemplares similares